Protocol Ledger

NCT04079166 · Phase II · ACTIVE NOT RECRUITING

SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)

Interventional Phase II clinical trial protocol NCT04079166 sponsored by Scancell in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-08-19 Enrollment: 173 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04079166
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)173 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04079166
Protocol FieldVerified Registry Value
NCT IdentifierNCT04079166
Consolidated Lead SponsorScancell
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment173 participants (ESTIMATED)
Registered Start Date2019-08-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04079166
Hospital Research SiteLocationSite Profile
The Royal Marsden NHS Foundation TrustLondon, United KingdomOpen Hospital Dossier ->
The Christie NHS Foundation TrustManchester, United KingdomOpen Hospital Dossier ->
Nottingham University Hospitals NHS TrustNottingham, United KingdomOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI